Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
8
CGTX Quote, Financials, Valuation and Earnings
Last price:
$0.32
Seasonality move
:
-11.05%
Day range:
$0.31 - $0.35
52-week range:
$0.31 - $2.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.08x
Volume:
1.2M
Avg. volume:
769.2K
1-year change:
-83.89%
Market cap:
$20.3M
Revenue:
--
EPS (TTM):
-$0.87
Analysts' Opinion
-
Consensus RatingCognition Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.40, Cognition Therapeutics has an estimated upside of 1550.87% from its current price of $0.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.33.
Fair Value
-
According to the consensus of 4 analysts, Cognition Therapeutics has 1550.87% upside to fair value with a price target of $5.40 per share.
CGTX vs. S&P 500
-
Over the past 5 trading days, Cognition Therapeutics has underperformed the S&P 500 by -26.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cognition Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cognition Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cognition Therapeutics reported revenues of --.
Earnings Growth
-
Cognition Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cognition Therapeutics reported earnings per share of -$0.17.
Enterprise value:
-4.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$21.3M | -$25.9M | -$34.4M | -$8.4M | -$7.7M | |
| EBITDA | -$21.1M | -$25.5M | -$33.7M | -$8.1M | -$7.8M | |
| Diluted EPS | -$0.91 | -$0.86 | -$0.87 | -$0.27 | -$0.17 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.9M | $59M | $47.6M | $34.2M | $29.6M | |
| Total Assets | $7.1M | $59.1M | $50.4M | $35.2M | $30.2M | |
| Current Liabilities | $3.3M | $7.9M | $7.8M | $10.2M | $11.1M | |
| Total Liabilities | $75.3M | $7.9M | $10.2M | $10.7M | $11.5M | |
| Total Equity | -$68.2M | $51.3M | $40.2M | $24.5M | $18.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.5M | -$16M | -$28.5M | -$5.5M | -$8.4M | |
| Cash From Investing | -$171K | -$147K | -$4K | -$30K | -$1K | |
| Cash From Financing | $5.5M | $4.5M | $23.6M | $2.4M | $11.4M | |
| Free Cash Flow | -$18.7M | -$16.2M | -$28.5M | -$5.5M | -$8.4M | |
CGTX
Sector
Market Cap
$20.3M
$33.7M
Price % of 52-Week High
11.09%
40%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-83.89%
-46.85%
Beta (5-Year)
--
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.37
200-day SMA
Sell
Level
$0.72
Bollinger Bands (100)
Sell
Level
0.41 - 0.69
Chaikin Money Flow
Sell
Level
-344.6M
20-day SMA
Sell
Level
$0.42
Relative Strength Index (RSI14)
Sell
Level
30.42
ADX Line
Sell
Level
27.64
Williams %R
Buy
Level
-88.7122
50-day SMA
Sell
Level
$0.50
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
204.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Stock Forecast FAQ
In the current month, CGTX has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CGTX average analyst price target in the past 3 months is $5.40.
-
Where Will Cognition Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cognition Therapeutics share price will rise to $5.40 per share over the next 12 months.
-
What Do Analysts Say About Cognition Therapeutics?
Analysts are divided on their view about Cognition Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cognition Therapeutics is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Cognition Therapeutics's Price Target?
The price target for Cognition Therapeutics over the next 1-year time period is forecast to be $5.40 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CGTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cognition Therapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CGTX?
You can purchase shares of Cognition Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cognition Therapeutics shares.
-
What Is The Cognition Therapeutics Share Price Today?
Cognition Therapeutics was last trading at $0.32 per share. This represents the most recent stock quote for Cognition Therapeutics. Yesterday, Cognition Therapeutics closed at $0.33 per share.
-
How To Buy Cognition Therapeutics Stock Online?
In order to purchase Cognition Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 23.28% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 20.24% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 20.47% over the past day.
